Tags: Drug.

Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in Phase 3 of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are proteins whichconvert the energy derived from the hydrolysis of ATP to structural changes in protein molecules in order to perform coupling thus discharging medicine from cells.

Zosuquidar.svg
ATC prefix
none
CAS number
167354-41-8
FDA UNII code
AB5K82X98Y
IUPAC name
(2R)-​1-​4-​[(1aR10bS)-​11-​difluoro-​11a610b-​tetrahydrodibenzo​[ae]​cyclopropa​[c]​[7]​annulen-​6-​yl-​3-​(quinolin-​5-​yloxy)​propan-​2-​ol
PubChem
153997

Loading...

This page contains content from the copyrighted Wikipedia article "Zosuquidar"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.